Successful treatment of severe refractory chronic actinic dermatitis with upadacitinib: a case series of four patients.
Nidia Planella-Fontanillas, Jorge Magdaleno-Tapial, Vicente Expósito-Serrano et al.
✦ AI-curated · Sources linked
Case in brief
Four men aged 44-65 with severe refractory chronic actinic dermatitis (CAD) unresponsive to multiple systemic treatments were evaluated. They exhibited significant photosensitivity, with two presenting erythroderma. After extensive investigations ruled out cutaneous T-cell lymphoma, upadacitinib was administered off-label. All patients showed clinical improvement within 4 weeks, achieving complete remission between 4 and 8 weeks, sustained for up to 12 months.
Diagnostic / clinical pearl
In cases of severe refractory chronic actinic dermatitis, upadacitinib may provide a viable treatment option, especially when conventional therapies fail.
Why it matters
This case series highlights the potential of selective Janus kinase 1 inhibition in managing severe CAD, expanding therapeutic options for this challenging condition.